TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) just unveiled an announcement.
Guangzhou Baiyunshan Pharmaceutical Holdings Company announced a plan for GP Corp. to engage in account receivable asset-backed securitization, aiming to issue securities worth up to RMB3 billion. This strategic move is expected to enhance liquidity and optimize asset management, potentially strengthening the company’s financial position and market competitiveness.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company operates in the pharmaceutical industry, focusing on the sale of drugs and medical devices. Its primary market includes public hospitals and commercial companies, particularly those of Grade II or above.
YTD Price Performance: 8.61%
Average Trading Volume: 1,215,256
Technical Sentiment Signal: Buy
Current Market Cap: HK$44.03B
See more insights into 0874 stock on TipRanks’ Stock Analysis page.